Completed NA NCT00002331

The Safety and Effectiveness of Clarithromycin Plus Ethambutol Used With or Without Clofazimine in the Treatment of MAC in Patients With AIDS

A Randomized Open-Label Study of the Tolerability and Efficacy of Clarithromycin and Ethambutol in Combination With or Without Clofazimine for the Treatment of Disseminated MAC (dMAC) in Patients With AIDS

Sponsor: Abbott

Conditions HIV Infections Mycobacterium Avium-intracellular Infection

Interventions Clarithromycin Clofazimine Ethambutol hydrochloride

Updated 6 times since 2017 Last updated: Jan 15, 2015 Started: Jan 31, 1994 Primary completion: Mar 31, 1995 Completion: Mar 31, 1995

This NA trial investigates HIV Infections and Mycobacterium Avium-intracellular Infection and is currently completed. Abbott leads this study, which shows 6 recorded versions since 1994 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed NA
Sep 2024 — Sep 2025 [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Jan 1994

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abbott

Data source: Abbott

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Chapel Hill, United States , Chicago, United States , Condado San Juan, Puerto Rico , Dallas, United States , Houston, United States , Los Angeles, United States , Miami, United States , Nashville, United States , New Orleans, United States and 7 more locations